Press release
Hypertrophic Cardiomyopathy Therapeutics Market to reach USD 1.2 Billion by 2020
Browse Hypertrophic Cardiomyopathy Therapeutics Market – Global HCM Drug Classes, Clinical Pipeline Analysis and Forecast 2013-2020 at http://www.ihealthcareanalyst.com/report/hypertrophic-cardiomyopathy-therapeutics-market/
Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease with a diverse clinical presentation and course. It is also a common inherited heart disease with serious adverse outcomes, including heart failure, arrhythmias, and sudden cardiac death. Medications include beta blockers, calcium channel blockers, and, rarely, diltiazem, amiodarone, and disopyramide. The hypertrophic cardiomyopathy therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (antiarrhythmic agents, anticoagulants, beta adrenergic blocking agents, and calcium channel blockers) and clinical pipeline analysis of phase 1, 2 and 3 drugs, and forecasts growth trends (CAGR% - 2015 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.
The global hypertrophic cardiomyopathy therapeutics market is segmented as:
1. Drug Class
1.1. Antiarrhythmic Agents
1.2. Anticoagulants
1.3. Beta Adrenergic Blocking Agents
1.4. Calcium Channel Blockers
2. Pipeline Analysis
2.1. Clinical Trials (Phase 1, 2 and 3)
3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World
4. Company Profiles
4.1. Astra Zeneca plc
4.2. Concordia Healthcare Corp.
4.3. Gilead Sciences, Inc.
4.4. Merck & Co., Inc.
4.5. Mylan N.V.
4.6. Novartis AG
4.7. Pfizer, Inc.
4.8. Sanofi S.A.
4.9. Teva Pharmaceutical Industries Ltd.
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
http://www.ihealthcareanalyst.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertrophic Cardiomyopathy Therapeutics Market to reach USD 1.2 Billion by 2020 here
News-ID: 345853 • Views: …
More Releases from iHealthcareAnalyst, Inc.
Global Amyotrophic Lateral Sclerosis Devices Market $19.5 Billion by 2029
The global market for amyotrophic lateral sclerosis devices or motor neuron disease devices anticipated to reach $19.5 billion by 2029, growing at a CAGR of 7.3% over the forecast period, driven by increasing incidence, rising geriatric population, lack of curative treatment, growing public awareness, and technological advancements in palliative care.
https://www.ihealthcareanalyst.com/global-amyotrophic-lateral-sclerosis-devices-market/
Amyotrophic lateral sclerosis or Lou Gehrig's disease or motor neuron disease (MND) is characterized by progressive degeneration of the motor nerve…
Global Blood Gas Monitoring Products Market Growing at CAGR of 6.2% to Reach $5. …
The global market for blood gas monitoring products is estimated to reach $5.5 billion by the end of 2025, expanding at a CAGR of 6.2% during the forecast period, supported by growing geriatric population, rising prevalence of chronic diseases, and technological advances.
The global blood gas monitoring devices market research report provides market size (Revenue US$ Million 2017 to 2025), market share analysis, growth trends and forecast (CAGR%, 2019 to 2025).…
Advances in Mobile Connectivity Services to Drive Telemedicine Technologies and …
According to a new market research report Telemedicine Technologies and Services Market 2015-2023 published by iHealthcareAnalyst, Inc., the global computer-aided detection market to reach US$ 73.2 Billion by 2023, expanding at a CAGR of 13.5% from 2018-2023.
Visit the Global Telemedicine Technologies and Services Market Analysis and Forecast 2018-2023 report at https://www.ihealthcareanalyst.com/report/telemedicine-technologies-services-market/
The global telemedicine technologies and services market newly published (updated 2018) report estimates the market size (US$ million 2015-2023)…
Global Internet Pharmacies Market to Cross US$ 100 Billion by 2023
The global internet pharmacies market is estimated to reach US$ 106 Billion by 2023, growing at a CAGR of 15.7% over the forecast period, driven by rising personal disposable income, lower prices, surge in internet penetration, stupendous growth of online retail market and a large number of online players entering the online healthcare product segment.
The major players are in a race to increase their share in the industry by…
More Releases for Ana
HISTORIC SANTA ANA LANDMARK REVITALIZED THROUGH ADAPTIVE REUSE ORDINANCE
Alliant Strategic delivers a solution by providing one of the first adaptive reuse apartment projects to fulfill a critical need for the local Santa Ana community. The newly renovated development, 888 on Main, will add 148 apartments to Downtown’s historic core, one of the most densely populated residential markets in the nation that suffers from an extreme housing shortage. With the building shell, core, mechanical systems, and underground parking already…
Antechamber Solo show Ana Mazzei
Ana Mazzei
Antechamber
12 November 2018– 5 January 2019
In her first solo exhibition at Green Art Gallery, Ana Mazzei fully embraces the notion of theatricality and
spectatorship, both very central to her practice, to present a group of new works specifically created for the space.
Titled Antechamber, the show is staged as an intermediary space between the real world outside the gallery and
an imaginary ‘other space’.
Walking along this in-between space, viewers have to negotiate…
Intravenous Solutions Market 2018-2025 Growth Factors Ana
This report studies the global Intravenous Solutions market, analyzes and researches the Intravenous Solutions development status and forecast in United States, EU, Japan, China, India and Southeast Asia.
This report focuses on the top players in global market, like
Baxter
Hospira
B. Braun Melsungen
Fresenius Kabi
Claris Lifesciences
Grifols
Vifor Pharma
JW Life Science
Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia
Browse the full report…
direct/ All Nippon Airways: ANA Interim results amendment
In line 5 of paragraph 1, Operating Profit is reported as having fallen to 696.1 billion yen. This is in fact the figure for Operating Costs. The correct figure for Operating Profit is 67.0 billion yen.
Please accept our apologies for this mistake. The first chart on the first page, entitled Consolidated Financial Performance, gives the correct figures.
The announcement distributed by Hugin directnews.
The issuer is solely responsible for the…
direct/ All Nippon Airways: ANA Interim FY07 Profitable
ANA Reports Profitable First Six Months to Fiscal Year 2007
- record revenue on strong international growth
TOKYO October 31, 2007 ANA Group today reported a record consolidated net profit of 105.5 billion yen on record revenue of 763.2 billion yen for first six months of fiscal year 2007, ended September 30, a 217% and 1.4% increase respectively. Net profit was boosted considerably by the sale of ANA Group´s hotel assets on…
direct/ All Nippon Airways: ANA Corporate Plan FY2007
Japan´s first all business Class Jet to Link Tokyo and Mumbai -
TOKYO January 25, 2007 ANA today announced its corporate plan for the 2007 fiscal year, April 1, 2007 - March 31, 2008. Fiscal 2007 constitutes the second year of ANA´s Medium-Term Strategy FY2006-2009, the aim of which is to establish ANA as Asia´s No 1 airline for quality, customer satisfaction and value creation in line with the future…
